 Care Therapeutics Inc NASDAQ:CARA is seeing a influx of options activity today, following news that the U.S. Food and Drug Administration FDA approved its Korsuva difelikefalin injection to treat moderate-to-severe itching in adult patients with chronic kidney disease undergoing dialysis. 